Stocktoria

Nurix Therapeutics, Inc. NRIX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-07-24

Nurix Therapeutics, Inc. statistics & valuation

Market cap$2.4B
P / S28.2×
P / B4.4×
Net margin-314.9%
Return on equity-49.1%
FCF margin-313.7%
Return on capital-47.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-69.70% -242.70% -393.90% -466.90% -187.00% -354.90% -314.90% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-71.50% -364.70% -396.30% -476.00% -201.40% -390.50% -340.20% 2019202020212022202320242025
Return on equity (%)
-14.90% -34.20% -59.40% -71.80% -36.70% -49.10% 2019202020212022202320242025
Shares outstanding
3.6M 38.9M 44.7M 48.6M 54.3M 75.9M 101.8M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-49.30% -10.90% -24.60% -43.30% -40.50% -28.90% -38.40% 2019202020212022202320242025
Free cash flow margin (%)
-3.40% -26.00% -302.60% -445.40% -116.60% -333.40% -313.70% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.73 -$3.71 -$2.65 -$2.88 -$3.05 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-340.2%-390.5%-201.4%-476.0%-396.3%-364.7%-71.5%
Net margin-314.9%-354.9%-187.0%-466.9%-393.9%-242.7%-69.7%
FCF margin-313.7%-333.4%-116.6%-445.4%-302.6%-26.0%-3.4%
Return on assets-38.4%-28.9%-40.5%-43.3%-24.6%-10.9%-49.3%
Return on equity-49.1%-36.7%-71.8%-59.4%-34.2%-14.9%37.6%
Current ratio7.026.463.404.514.706.702.44

Computed from company filings · US · as of 2025-11-30. Facts plus Stocktoria's own computed scores — not investment advice.